The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
May 29, 2026 4:20 AM
A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.
Keep Reading
Humanoids are moving from research labs into real industries — and capital is finally catching up.
Updated
January 8, 2026 6:31 PM
A face of a humanoid robot, side view on black background. PHOTO: UNSPLASH
Humanoid robots are shifting from sci-fi speculation to engineering reality, and the pace of progress is prompting investors to reassess how the next decade of physical automation will unfold. ALM Ventures has launched a new US$100 million early-stage fund aimed squarely at this moment—one where advances in robot control, embodied AI and spatial intelligence are beginning to converge into something commercially meaningful.
ALM Ventures Fund I, is designed for the earliest stages of company formation, targeting seed and pre-seed teams building the foundations of humanoid deployment. It’s a concentrated fund that seeks to take early ownership in a sector that many now consider the next major technological frontier.
For Founder and General Partner Modar Alaoui, the timing is not accidental. “After years of research, humanoids are finally entering a phase where performance, reliability and cost are converging toward commercial viability”, he said. “What the category needs now is focused capital and deep technical diligence to turn prototypes into scalable, enduring companies”.
That framing captures a shift happening across robotics: the field is moving out of the lab and into early commercial readiness. Improvements in perception systems, model-based reasoning and motion control are accelerating the transition. Advances in simulation are also lowering the complexity and cost of integrating humanoid platforms into real environments. As these systems become more capable, the gap between research prototypes and market-ready products is narrowing.
ALM Ventures is positioning itself at this inflection point. Fund I’s thesis centers on the core technologies required to scale humanoids safely and economically. This includes next-generation robot platforms, spatial reasoning engines, embodied intelligence models, world-modeling systems and the infrastructure needed for early deployment. Rather than chasing every robotics trend, the fund is concentrating on the essential layers that will determine whether humanoids can work reliably outside controlled settings.
The firm isn’t starting from zero. During the fund’s formation, ALM Ventures made ten early investments that directly align with its investment focus. The portfolio includes companies building at different layers of the humanoid stack, such as Sanctuary AI, Weave Robotics, Emancro, High Torque Robotics, MicroFactory, Mbodi, Adamo, Haptica Robotics, UMA and O-ID. The list reflects a broad but intentional spread, from hardware to intelligence to manufacturing approaches, all oriented toward enabling scalable physical AI.
Beyond capital, ALM Ventures has been shaping the ecosystem through its global Humanoids Summit series in Silicon Valley, London and Tokyo. The series gives the firm early visibility into emerging technologies, pre-incorporation teams and the senior leaders steering the global robotics landscape. That vantage point has helped the firm identify where commercialization is truly taking root and where bottlenecks still exist.
The rise of humanoids is often compared to the early days of self-driving cars: a long arc of research suddenly meeting an acceleration point. What separates this moment is that advances in embodied AI and spatial intelligence are giving robots a more intuitive understanding of the physical world, making them easier to deploy, teach and scale. ALM Ventures’ Fund I is an attempt to capture that transition while shaping the companies that could define the next technological era.
With US$100 million dedicated to the earliest builders in the space, ALM Ventures is signaling its belief that humanoids are not just another robotics cycle—they may be the next major platform shift in AI.